105 related articles for article (PubMed ID: 30529791)
1. Liposomal steroid nano-drug is superior to steroids as-is in mdx mouse model of Duchenne muscular dystrophy.
Turjeman K; Yanay N; Elbaz M; Bavli Y; Gross M; Rabie M; Barenholz Y; Nevo Y
Nanomedicine; 2019 Feb; 16():34-44. PubMed ID: 30529791
[TBL] [Abstract][Full Text] [Related]
2. Motor performance of young dystrophic mdx mice treated with long-circulating prednisolone liposomes.
Weller C; Zschüntzsch J; Makosch G; Metselaar JM; Klinker F; Klinge L; Liebetanz D; Schmidt J
J Neurosci Res; 2012 May; 90(5):1067-77. PubMed ID: 22253213
[TBL] [Abstract][Full Text] [Related]
3. Treatment with human immunoglobulin G improves the early disease course in a mouse model of Duchenne muscular dystrophy.
Zschüntzsch J; Zhang Y; Klinker F; Makosch G; Klinge L; Malzahn D; Brinkmeier H; Liebetanz D; Schmidt J
J Neurochem; 2016 Jan; 136(2):351-62. PubMed ID: 26230042
[TBL] [Abstract][Full Text] [Related]
4. Zidovudine ameliorates pathology in the mouse model of Duchenne muscular dystrophy via P2RX7 purinoceptor antagonism.
Al-Khalidi R; Panicucci C; Cox P; Chira N; Róg J; Young CNJ; McGeehan RE; Ambati K; Ambati J; Zabłocki K; Gazzerro E; Arkle S; Bruno C; Górecki DC
Acta Neuropathol Commun; 2018 Apr; 6(1):27. PubMed ID: 29642926
[TBL] [Abstract][Full Text] [Related]
5. Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy.
Pinniger GJ; Terrill JR; Assan EB; Grounds MD; Arthur PG
J Physiol; 2017 Dec; 595(23):7093-7107. PubMed ID: 28887840
[TBL] [Abstract][Full Text] [Related]
6. A new therapeutic effect of simvastatin revealed by functional improvement in muscular dystrophy.
Whitehead NP; Kim MJ; Bible KL; Adams ME; Froehner SC
Proc Natl Acad Sci U S A; 2015 Oct; 112(41):12864-9. PubMed ID: 26417069
[TBL] [Abstract][Full Text] [Related]
7. Contractile efficiency of dystrophic mdx mouse muscle: in vivo and ex vivo assessment of adaptation to exercise of functional end points.
Capogrosso RF; Mantuano P; Cozzoli A; Sanarica F; Massari AM; Conte E; Fonzino A; Giustino A; Rolland JF; Quaranta A; De Bellis M; Camerino GM; Grange RW; De Luca A
J Appl Physiol (1985); 2017 Apr; 122(4):828-843. PubMed ID: 28057817
[TBL] [Abstract][Full Text] [Related]
8. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys.
St Andre M; Johnson M; Bansal PN; Wellen J; Robertson A; Opsahl A; Burch PM; Bialek P; Morris C; Owens J
Skelet Muscle; 2017 Nov; 7(1):25. PubMed ID: 29121992
[TBL] [Abstract][Full Text] [Related]
9. Effects of fish oil containing eicosapentaenoic acid and docosahexaenoic acid on dystrophic mdx mice.
Fogagnolo Mauricio A; Minatel E; Santo Neto H; Marques MJ
Clin Nutr; 2013 Aug; 32(4):636-42. PubMed ID: 23218947
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti-inflammatory effects in mdx mice with Duchenne muscular dystrophy.
Nio Y; Tanaka M; Hirozane Y; Muraki Y; Okawara M; Hazama M; Matsuo T
FASEB J; 2017 Dec; 31(12):5307-5320. PubMed ID: 28798156
[TBL] [Abstract][Full Text] [Related]
11. Amitriptyline is efficacious in ameliorating muscle inflammation and depressive symptoms in the mdx mouse model of Duchenne muscular dystrophy.
Manning J; Kulbida R; Rai P; Jensen L; Bouma J; Singh SP; O'Malley D; Yilmazer-Hanke D
Exp Physiol; 2014 Oct; 99(10):1370-86. PubMed ID: 24972834
[TBL] [Abstract][Full Text] [Related]
12. Melatonin improves muscle function of the dystrophic mdx5Cv mouse, a model for Duchenne muscular dystrophy.
Hibaoui Y; Reutenauer-Patte J; Patthey-Vuadens O; Ruegg UT; Dorchies OM
J Pineal Res; 2011 Sep; 51(2):163-71. PubMed ID: 21486366
[TBL] [Abstract][Full Text] [Related]
13. Effect of a long-term treatment with metformin in dystrophic mdx mice: A reconsideration of its potential clinical interest in Duchenne muscular dystrophy.
Mantuano P; Sanarica F; Conte E; Morgese MG; Capogrosso RF; Cozzoli A; Fonzino A; Quaranta A; Rolland JF; De Bellis M; Camerino GM; Trabace L; De Luca A
Biochem Pharmacol; 2018 Aug; 154():89-103. PubMed ID: 29684379
[TBL] [Abstract][Full Text] [Related]
14. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol ameliorates muscular pathology in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy.
Hori YS; Kuno A; Hosoda R; Tanno M; Miura T; Shimamoto K; Horio Y
J Pharmacol Exp Ther; 2011 Sep; 338(3):784-94. PubMed ID: 21652783
[TBL] [Abstract][Full Text] [Related]
16. Increasing taurine intake and taurine synthesis improves skeletal muscle function in the mdx mouse model for Duchenne muscular dystrophy.
Terrill JR; Pinniger GJ; Graves JA; Grounds MD; Arthur PG
J Physiol; 2016 Jun; 594(11):3095-110. PubMed ID: 26659826
[TBL] [Abstract][Full Text] [Related]
17. Sensorimotor control of breathing in the mdx mouse model of Duchenne muscular dystrophy.
Burns DP; Roy A; Lucking EF; McDonald FB; Gray S; Wilson RJ; Edge D; O'Halloran KD
J Physiol; 2017 Nov; 595(21):6653-6672. PubMed ID: 28952155
[TBL] [Abstract][Full Text] [Related]
18. Increased plasma lipid levels exacerbate muscle pathology in the mdx mouse model of Duchenne muscular dystrophy.
Milad N; White Z; Tehrani AY; Sellers S; Rossi FMV; Bernatchez P
Skelet Muscle; 2017 Sep; 7(1):19. PubMed ID: 28899419
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of PEGylated insulin-like growth factor I for skeletal muscle disease evaluated in two murine models of muscular dystrophy.
Gehrig SM; van der Poel C; Hoeflich A; Naim T; Lynch GS; Metzger F
Growth Horm IGF Res; 2012 Apr; 22(2):69-75. PubMed ID: 22424862
[TBL] [Abstract][Full Text] [Related]
20. Identification of plasma interleukins as biomarkers for deflazacort and omega-3 based Duchenne muscular dystrophy therapy.
de Carvalho SC; Matsumura CY; Santo Neto H; Marques MJ
Cytokine; 2018 Feb; 102():55-61. PubMed ID: 29276972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
